Graypoint LLC Sells 533 Shares of Danaher Co. (NYSE:DHR)

Graypoint LLC cut its position in shares of Danaher Co. (NYSE:DHR) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,598 shares of the conglomerate’s stock after selling 533 shares during the period. Graypoint LLC’s holdings in Danaher were worth $3,121,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the third quarter valued at about $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter worth about $50,000. Darwin Wealth Management LLC acquired a new position in Danaher in the 3rd quarter valued at about $55,000. Finally, Modus Advisors LLC bought a new position in Danaher in the 4th quarter valued at about $56,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 1.3 %

Shares of DHR stock traded down $3.01 on Friday, hitting $235.08. The company had a trading volume of 2,863,201 shares, compared to its average volume of 2,863,129. The firm has a market cap of $169.79 billion, a P/E ratio of 44.86, a P/E/G ratio of 4.33 and a beta of 0.83. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock’s 50-day moving average is $235.93 and its two-hundred day moving average is $253.88.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 EPS. The business’s revenue was up 3.1% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. Citigroup decreased their target price on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday. Royal Bank of Canada lowered their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Finally, UBS Group decreased their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.